

## **BMP-2 Increases Survival of Mesenchymal Stem Cells and Fracture Healing When Deployed in Photopolymerizable Hydrogels**

*Motasem Refaat, MD<sup>1</sup>; Nina Vollmer, PhD<sup>2</sup>; Steve Ho, BS<sup>2</sup>; Oju Jeon, PhD<sup>2</sup>; Eben Alsberg, PhD<sup>3</sup>; Kent Leach, PhD<sup>2</sup>; Mark Lee, MD<sup>1</sup>;*

*<sup>1</sup>Univ of California (Davis) Med Ctr, Sacramento, California, USA;*

*<sup>2</sup>University of California at Davis, Davis, California, USA;*

*<sup>3</sup>Case Western Reserve University, Sacramento, California, USA*

**Purpose:** Mesenchymal stem cells (MSCs) have great therapeutic potential for the repair of nonhealing bone defects due to their proliferative capacity, multilineage potential, trophic factor secretion, and lack of immunogenicity. However, a major challenge to the translation of cell-based therapies into bone regeneration constructs is ensuring their survival and function upon implantation. Composite constructs utilizing growth factors such as bone morphogenetic proteins (eg, BMP-2) and MSCs are under investigation for use in the clinic, yet the effect of BMP-2 delivery on MSC survival and function remains poorly studied. We investigated cell survival and subsequent effects on bone regeneration in MSCs codelivered with BMP-2. Our aim was to determine the efficacy and survival of MSCs when delivered with BMP-2 via a photopolymerized, modified alginate carrier in a rat critical size defect (CSD) model.

**Methods:** Diaphyseal CSDs (6 mm) were created in the right femora of 10- to 12-week-old male athymic rats and stabilized with a radiolucent PEEK (polyetheretherketone) plate and 6 angular stable bicortical titanium screws. Sodium alginate modified with methacrylate side chains, to enable photopolymerization, and Arg-Gly-Asp (RGD) peptide, to promote adhesion, was used as the carrier. Human MSCs genetically modified to express luciferase ( $3 \times 10^6$  cells/ $150 \mu\text{L}$  gel) were suspended in the gel, cross-linked (0.05% w/v photoinitiator  $3.5 \text{ mW/cm}^2$ ) for 30 min, and then incubated at  $37^\circ\text{C}$  in  $\alpha$ -MEM (minimum essential medium) up to 12 hours. Animals were randomly assigned to two treatment groups: (1) -BMP (alginate modified with the cell adhesive ligand sequence RGD) or (2) +BMP (RGD modified alginate containing  $2 \mu\text{g}$  BMP-2). Persistence of transplanted cells was determined by whole body bioluminescence at 1, 2, and 4 weeks. Surveillance radiographs were obtained at 4, 8, and 12 weeks, and scored 0 (no bone formation), 1 (possible union), or 2 (union). All rats were sacrificed at 12 weeks.

**Results:** Bioluminescence was used to assay cell viability of transplanted cells within the defect (Figure 1A). Alginate hydrogels containing BMP-2 had significantly more cells at each time point than gels without BMP-2 (Figure 1B). All animals in the BMP group demonstrated 100% radiographic union by 8 weeks. None of the rats in the RGD group fully united at the time of sacrifice.

**Conclusion:** The delivery of BMP-2 in RGD-modified alginate gels increased MSC survival compared to alginate with MSCs alone, resulting in increased bone formation in a critical size defect model. The interplay between BMP and cell survival using photopolymerized hydrogel systems merits further study.




Figure 1A: Representative bioluminescence at 4 weeks.




Figure 1B: Quantification of bioluminescence over time. (P<0.05 at all time points)

The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or medical device he or she wishes to use in clinical practice.